BOLT - CIK 0001641281
Bolt Biotherapeutics, Inc. (BOLT) reported net income of -$33.38M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$33.38M | +47.1% |
| FY 2024 | -$63.12M | +8.8% |
| FY 2023 | -$69.20M | +21.5% |
| FY 2022 | -$88.10M | +10.6% |
| FY 2021 | -$98.59M | -62.3% |
| FY 2020 | -$60.73M | - |
Bolt Biotherapeutics, Inc. (BOLT) reported net income of -$33.38M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Bolt Biotherapeutics, Inc.'s net income grew from -$60.73M to -$33.38M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.